Two Of The Cyclos Share At Least Three Ring Members (i.e., Bridged) Patents (Class 514/511)
-
Publication number: 20120172396Abstract: The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.Type: ApplicationFiled: February 7, 2012Publication date: July 5, 2012Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNGInventors: Denis CARNIATO, Christine CHARON, Johannes GLEITZ, Didier ROCHE, Bjoern HOCK
-
Patent number: 8211085Abstract: Therapeutic device intended for the selective cytoreductive treatment of an obstruction in a natural lumen or passage of the human or animal body, said lumen being obstructed by the effect of a local cell proliferation, said device comprising a tubular element, in particular of cylindrical shape, intended to be placed in said natural lumen and sufficiently flexible to conform to said natural lumen, but sufficiently rigid to maintain an artificial channel in said lumen. The tubular element supports lengthwise a medicinal sleeve which is intended to come into line with, and into contact with, the obstruction once the natural lumen has been intubated, and is designed to deliver locally, at least in its outer surface portion, at least one therapeutic agent which is cytoreductive, in particular cytotoxic, through contact with the cells under whose effect said lumen is obstructed.Type: GrantFiled: December 22, 2004Date of Patent: July 3, 2012Inventor: Marian Devonec
-
Patent number: 8211941Abstract: One of the major disabling symptoms of gastroparesis is nausea and vomiting which can be difficult to control with currently available treatments. It is postulated that signaling of gastrointestinal causes of nausea starts with activation of vagal afferent nerves that trigger the central emetic pathway. Most vagal afferent nerves are unmyelinated C-fibers, many of which express the vanilloid receptor TRPV1 and respond to capsaicin. Resiniferatoxin is a very potent capsaicin analogue that has a much more favorable ratio of desensitization to excitation than capsaicin leading to more effective desensitization without irritation. The present invention describes methods of alleviating acute or chronic nausea, vomiting by the administration of resiniferatoxin.Type: GrantFiled: April 11, 2008Date of Patent: July 3, 2012Assignee: The Board of Regents of the University of Texas SystemInventors: Pankaj J. Pasricha, Jiande Chen, Rami Hawari
-
Publication number: 20120122870Abstract: Ischemia-reperfusion injury remains a primary cause of morbidity and mortality in individuals who experience disruption of normal blood flow to one or more major organs. For example, there are no clinically proven strategies that prevent acute renal failure following cardiac surgery. The present invention provides a variety of methods for the treatment or prevention of ischemia-reperfusion injury. In one aspect of the invention, a method for treating or preventing ischemia-reperfusion injury includes administering to a subject an effective amount of a sphingosine kinase inhibitor. Sphingosine kinase inhibitors are very effective in the protection against IR-induced acute renal failure and liver failure. Moreover, the effects occur very early after administration, requiring only a very short time of treatment. Toxicology studies with sphingosine kinase inhibitors demonstrate that they have low toxicity, even in long-term treatment.Type: ApplicationFiled: May 10, 2010Publication date: May 17, 2012Applicants: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT, APOGEE BIOTECHNOLOGY CORPORATIONInventors: Charles D. Smith, Zhi Zhong, Lynn W. Maines
-
Publication number: 20120095004Abstract: The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.Type: ApplicationFiled: October 19, 2011Publication date: April 19, 2012Applicant: APOGEE BIOTECHNOLOGY CORPORATIONInventors: Charles D. Smith, Kevin J. French, Yan Zhuang
-
Patent number: 8129429Abstract: The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.Type: GrantFiled: January 12, 2009Date of Patent: March 6, 2012Assignees: Reata Pharmaceuticals, Inc., Trustees of Dartmouth CollegeInventors: Michael B. Sporn, Karen T. Liby, Gordon W. Gribble, Tadashi Honda, Robert M. Kral, Colin J. Meyer
-
Publication number: 20120035260Abstract: Use of tellurium-containing compounds in a method of conception and/or for maintaining and/or augmenting fertility in female following chemotherapy and/or radiotherapy is disclosed. The tellurium-containing compound is utilized in combination with a chemotherapeutic agent and/or radiation, such that the female treated by the chemotherapeutic agent and/or radiation and by the tellurium-containing compound is instructed to refrain from conceptive sex for a pre-determined time period, following the chemotherapy and/or radiotherapy, during which conception is undesired. The tellurium-containing compound is utilized in combination with a chemotherapeutic agent and/or radiation, such that the female treated by the chemotherapeutic agent and/or radiation and by the tellurium-containing compound is instructed to refrain from sex and/or from reproduction for a pre-determined time period, and is then allowed to practice reproduction.Type: ApplicationFiled: January 7, 2010Publication date: February 9, 2012Applicant: BIOMAS LTD.Inventors: Benjamin Sredni, Dror Meirow, Michael Albeck, Benjamin Ron
-
Publication number: 20110319454Abstract: The invention provides well defined compounds having FPRL-1 agonist or antagonist activity. As such, the compounds of the invention are useful for treating a variety of ocular disorders.Type: ApplicationFiled: June 24, 2011Publication date: December 29, 2011Applicant: ALLERGAN, INC.Inventors: Richard L. Beard, John E. Donello, Vidyasagar Voligonda, Michael E. Garst
-
Patent number: 8049038Abstract: This invention concerns compounds of adamantanamines and neramexane, including their pharmaceutically-acceptable salts, diesterioisomers, and formulations for treating Alzheimer's related dementias, depression, AIDS related dementias, as antivirals, inflammatory diseases such as rheumatoid arthritis, and cerebral ischemia, hyperlipidemia, and diabetes.Type: GrantFiled: May 7, 2011Date of Patent: November 1, 2011Assignee: SSV Therapeutics, Inc.Inventor: Om P. Goel
-
Publication number: 20110257262Abstract: The present invention relates to a novel crystalline form of ingenol mebutate, methods of preparation thereof, and to its use. More specifically, the invention relates to the conversion of amorphous ingenol mebutate (ingenol-3-angelate, PEP005) to a crystalline form, which was characterized by single crystal X-Ray crystallography (XRC), attenuated total reflectance Fourier transform infrared (FTIR-ATR) spectroscopy and Differential Scanning calorimetry (DSC).Type: ApplicationFiled: April 18, 2011Publication date: October 20, 2011Applicant: LEO PHARMA A/SInventor: Steven Martin OGBOURNE
-
Publication number: 20110213002Abstract: The present invention relates generally to chemical agents useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and avian species. More particularly, the present invention provides a chemical agent of the macrocyclic diterpene family obtaining from a member of the Euphorbiaceae family of plants or botanical or horticultural relatives thereof or derivatives or chemical analogues or chemically synthetic forms of the agents for use in the treatment or prophylaxis of an inflammatory condition or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammal, animal or avian species.Type: ApplicationFiled: February 24, 2011Publication date: September 1, 2011Applicant: Peplin Research Pty Ltd.Inventors: James Harrison Aylward, Peter Gordon Parsons, Andreas Suhrbier, Kathleen Anne Turner
-
Publication number: 20110201545Abstract: A method of making a gel-type livestock feed includes initially forming a feed mixture by mixing feed nutrient components, water, alginate, and a calcium component insoluble in water or a sequestrate to inhibit the calcium component from reacting with the alginate. Once the feed mixture is formed, the calcium component is solubilized or the sequestrates affecting the reactivity between the alginate and the calcium component is removed such that a gel feed is formed that includes a gel matrix containing the feed nutrient components. The gel feed may then be fed to the livestock. In another aspect of the present invention, piglets are weaned by feeding the gel feed for at least seven days directly after weaning. The gel feed may also include protein derived from blood with or without egg protein.Type: ApplicationFiled: April 28, 2011Publication date: August 18, 2011Inventors: Kent Lanter, Brenda de Rodas, Bill L. Miller, Gary E. Fitzner
-
Publication number: 20110184022Abstract: Compounds of formula (I), which are 14-O-{[(optionally substituted hydroxy)cyclohexyl)sulfanyl]acetyl}mutilins further substituted at the cyclohexyl group by an acylated amino group, salts and solvates thereof, pharmaceutical compositions comprising such compounds and their use as a pharmaceutical, e.g. for the treatment of diseases mediated by microbes and for the treatment of inflammation where microbese are mediating said inflammation.Type: ApplicationFiled: August 17, 2009Publication date: July 28, 2011Applicant: NABRIVA THERAPEUTICS AGInventors: Rosemarie Mang, Werner Heilmayer
-
Carnitine conjugates of adamantanamines and neramexane derivatives as dual prodrugs for various uses
Patent number: 7977511Abstract: This invention concerns compounds of adamantanamines and neramexane, including their pharmaceutically-acceptable salts, diesterioisomers, and formulations for treating Alzheimer's related dementias, depression, AIDS related dementias, as antivirals, inflammatory diseases such as rheumatoid arthritis, and cerebral ischemia, hyperlipidemia, and diabetes.Type: GrantFiled: April 4, 2007Date of Patent: July 12, 2011Assignee: SSV Therapeutics, Inc.Inventor: Om P. Goel -
Patent number: 7879904Abstract: The present invention relates to a method for the treatment of cancer in a cancer patient.Type: GrantFiled: June 2, 2010Date of Patent: February 1, 2011Assignee: Tapestry Pharmaceuticals, Inc.Inventors: Jan Zygmunt, James Ferrara, James D. McChesney
-
Publication number: 20110021448Abstract: Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.Type: ApplicationFiled: December 4, 2009Publication date: January 27, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: BRUCE D. HAMMOCK, IN-HAE KIM, CHRISTOPHE MORISSEAU, TAKAHO WATANABE, JOHN W. NEWMAN
-
Patent number: 7838555Abstract: The present invention relates to the treatment of acne vulgaris in a subject by administering to the subject an ingenane of the formula wherein R24-R26 are herein defined.Type: GrantFiled: December 9, 2002Date of Patent: November 23, 2010Assignee: Peplin Research Pty LtdInventors: James Harrison Aylward, Peter Gordon Parsons, Andreas Suhrbier, Kathleen Anne Turner
-
Patent number: 7816389Abstract: 14-O—[(((C1-6)Alkoxy-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O—[(((C1-6)Mono- or dialkylamino-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Hydroxy-(C1-6)-alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Formyl-(C0-5)-alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Guanidino-imino-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Ureido-imino-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Thioureido-imino-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Isothioureido-imino-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins and their use as pharmaceuticals.Type: GrantFiled: January 11, 2007Date of Patent: October 19, 2010Assignee: Nabriva Therapeutics Forschungs GmbHInventors: Klaus Thirring, Gerd Ascher, Susanne Paukner, Werner Heilmayer, Rodger Novak
-
Publication number: 20100240746Abstract: Provided herein are optically active stereoisomers of tricylclodecan-9-yl xanthogenate, processes of preparation, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating one or more symptoms of a disease caused by a virus.Type: ApplicationFiled: July 3, 2008Publication date: September 23, 2010Applicant: LUMAVITA AGInventors: Miyuki Tomioka, Ko Hasegawa
-
Publication number: 20100204318Abstract: The present invention relates generally to the treatment of cutaneous lesions containing cells infected by a virus, as well as compositions for the treatment of such lesions. More specifically, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in treating lesions caused by infection with a papilloma virus, such as a mammalian papilloma virus, in particular a Human Papilloma Virus.Type: ApplicationFiled: April 30, 2008Publication date: August 12, 2010Applicant: PEPLIN RESEARCH PTY LTDInventors: Steven Martin Ogbourne, Andreas Suhrbier, James Harrison Aylward
-
Patent number: 7750041Abstract: The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one antihyperplastic agent is added that has a distribution ratio between butanol and water ?0.5. The lipophilic active agent is absorbed by the vascular wall fast and in sufficient quantity. The preparation may be a liquid that can pass through capillaries and may contain a contrast agent so that the active agent is transferred into the vascular wall without any additional effort while the usually required contrast radiograms are taken. The preparation may also be applied to a catheter.Type: GrantFiled: December 20, 2001Date of Patent: July 6, 2010Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Ulrich Speck, Brunn Scheller
-
Publication number: 20100048698Abstract: The present invention relates generally to chemical agents useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and avian species. More particularly, the present invention provides a chemical agent of the macrocyclic diterpene family obtaining from a member of the Euphorbiaceae family of plants or botanical or horticultural relatives thereof or derivatives or chemical analogues or chemically synthetic forms of the agents for use in the treatment or prophylaxis of an inflammatory condition or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammal, animal or avian species.Type: ApplicationFiled: August 18, 2009Publication date: February 25, 2010Applicant: PEPLIN RESEARCH PTY LTD.Inventors: James Harrison Aylward, Peter Gordon Parsons, Andreas Suhrbier, Kathleen Anne Turner
-
Publication number: 20090292017Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer.Type: ApplicationFiled: December 18, 2006Publication date: November 26, 2009Inventors: Marc Barry Brown, Michael Edward Donald Crowthers, Tahir Nazir
-
Patent number: 7618999Abstract: The present invention relates to a process of obtaining taxosteroids and precursors thereof from the hydrindane bicyclic ring system. The compounds have a tetracyclic system which combines the structural characteristics of taxanes, such as the bicyclo[5.3.1]undecane system (cycles A and B), fused to a six-membered ring (C), and of steroids, such as the CD bicycle, the A ring and the side chain (Sc). The process of preparing the compounds and their application as compositions with pharmacological properties of interest are described.Type: GrantFiled: July 2, 2004Date of Patent: November 17, 2009Assignee: Universidade de Santiago de CompostelaInventors: Juan Granja Guillán, Luis Castedo Expósito, Rebeca GarcÃa Fandiño
-
Publication number: 20090247521Abstract: The present invention generally relates to methods useful for a therapy using a class of urea or amide compounds and related compositions, wherein the compound is a soluble epoxide hydrolase inhibitor, for treating and ameliorating the symptoms of diseases related to endothelial dysfunction.Type: ApplicationFiled: December 23, 2008Publication date: October 1, 2009Inventors: Bhasker R. Aavula, Sampath-Kumar Anandan, Richard D. Gless, JR., Dinesh Patel, Gabor Rubanyi, Yi-Xin Wang, Heather K. Webb Hsu
-
Carnitine Conjugates of Adamantanamines and Neramexane Derivatives as Dual Prodrugs for Various Uses
Publication number: 20090246267Abstract: This invention concerns compounds of adamantanamines and neramexane, including their pharmaceutically-acceptable salts, diesterioisomers, and formulations for treating Alzheimer's related dementias, depression, AIDS related dementias, as antivirals, inflammatory diseases such as rheumatoid arthritis, and cerebral ischemia, hyperlipidemia, and diabetes.Type: ApplicationFiled: April 4, 2007Publication date: October 1, 2009Applicant: SSV Therapeutics, Inc.Inventor: Om P. Goel -
Patent number: 7534814Abstract: A compound of formula wherein R2 is arylene or heterocyclene; or R and R2 together with the nitrogen atom to which they are attached form non-aromatic heterocyclene; and the other residues have various meanings, useful as pharmaceuticals, e.g. antimicrobials.Type: GrantFiled: June 14, 2004Date of Patent: May 19, 2009Assignee: Nabriva Therapeutics AGInventors: Gerd Ascher, Heinz Berner, Johannes Hildebrandt
-
Publication number: 20090104126Abstract: A sulfamate compound corresponding to Formula I wherein R1 to R3 and n have defined meanings, pharmaceutical compositions comprising these compounds; a process for preparing these compounds, and the use of such compounds or compositions to treat or inhibit various disorders or disease states in patients in need thereof by administering to such a patient a therapeutically effective amount of such a compound.Type: ApplicationFiled: October 17, 2008Publication date: April 23, 2009Applicant: Solvay Pharmaceuticals GmbHInventors: Uwe SCHOEN, Harald Waldeck, Uwe Reinecker, Peter-Colin Gregory, Dania Reiche, Holger Sann, Michael Wurl, Jochen Antel
-
Publication number: 20090098066Abstract: Used as cooling agents are the compounds of 1/7-isopropyl-4/5-methyl-bicyclo[2.2.2]oct-5-ene derivatives of the formula (I) wherein R1 and R2 are independently hydrogen, hydroxyl, hydroxymethyl, carboxy, or C(O)NHR, wherein R is methyl, ethyl, propyl, isopropyl, or cyclopropyl; with the proviso that R1 and R2 are not both hydrogen.Type: ApplicationFiled: August 14, 2006Publication date: April 16, 2009Inventors: Christophe C. Galopin, Stefan Michael Furrer, Jay Patrick Slack, Pablo Victor Krawec, Karen Ann Bell
-
Patent number: 7485320Abstract: A liposome formulation for stably incorporating high content of hydrophobic substance is disclosed. The liposome includes two phospholipids with different phase transition temperatures such as saturated and unsaturated phosphatidyl cholines, hydrophobic substances, cholesterol, cholesterol derivatives, antioxidant and hydrophilic polymer-modified lipids such as MPEG-DSPE.Type: GrantFiled: July 23, 2003Date of Patent: February 3, 2009Assignee: Industrial Technology Research InstituteInventors: Pei Kan, Ae-June Wang, Won-Ko Chen, Chih-Wan Tsao
-
Publication number: 20080293678Abstract: The invention describes compositions and kits comprising at least qrie organic nitric oxide enhancing salt of an angiotensin converting enzyme inhibitor, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; Q) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia.Type: ApplicationFiled: March 17, 2006Publication date: November 27, 2008Applicant: NitroMed, Inc.Inventor: David S. Garvey
-
Publication number: 20080287442Abstract: 14-O—[(((C1-6)Alkoxy-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O—[(((C1-6)Mono- or dialkylamino-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Hydroxy-(C1-8)-alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Formyl-(C0-5)-alkyl)-phenylsulfanyl)-acetyl]-mutilins 14-O-[((Guanidino-imino-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Ureido-imino-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Thioureido-imino-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Isothioureido-imino-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins and their use as pharmaceuticals.Type: ApplicationFiled: January 11, 2007Publication date: November 20, 2008Applicant: Nabriva Therapeutics Forschungs GmbHInventors: Klaus Thirring, Gerd Ascher, Susanne Paukner, Werner Heilmayer, Rodger Novak
-
Patent number: 7449492Abstract: The present invention relates generally to chemical agents useful in the treatment and prophylaxis of infection by pathogenic or potentially pathogenic entities, or entities capable of opportunistic infection in mammals, including humans and primates, non-mammalian animals and avian species. More particularly, the present invention provides a chemical agent of the macrocyclic diterpene family obtainable from a member of the Euphorbiaceae family of plants or botanical or horticultural relatives thereof or derivatives or chemical analogues or chemically synthetic forms of the agents for use in the treatment or prophylaxis of infection by pathogenic entities in mammalian, animal and avian subjects.Type: GrantFiled: December 9, 2002Date of Patent: November 11, 2008Assignee: Peplin Research Pty, Ltd.Inventors: James Harrison Aylward, Peter Gordon Parsons, Andreas Suhrbier, Kathleen Anne Turner
-
Publication number: 20080275112Abstract: The present invention describes 1-aminoadamantane derivatives and 3-aminoadamantane-1-carboxylic derivatives in which the 5- or 7-position of the basic adamantane structure can be optionally substituted, methods for the production of the compounds based on the present invention, and methods for the coupling of the monomeric 3-aminoadamantane-1-carboxylic derivatives thus obtained to oligomers. The compounds based on the present invention are suitable for the utilisation as antiviral active ingredients, artificial ion channels, as well as for the therapy, diagnostics and prophylaxis of diseases in which a dysfunction of the GABA system occurs.Type: ApplicationFiled: July 22, 2005Publication date: November 6, 2008Inventors: Peter R. Schreiner, Lukas Wanka
-
Publication number: 20080206365Abstract: Provided are a certain compounds and compositions useful for inhibiting or activating the production of various types of cytokines. Also provided are certain compounds and compositions for preventing or treating various diseases attributable to abnormal cytokine production or compromised immunity.Type: ApplicationFiled: February 28, 2007Publication date: August 28, 2008Inventors: Yoshihisa Tachibana, Shoichiro Kurata, Yoshiteru Oshima, Kazunori Ueda, Haruhisa Kikuchil
-
Patent number: 7384977Abstract: Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.Type: GrantFiled: August 31, 2006Date of Patent: June 10, 2008Assignee: PG-TXL Company, L.P.Inventors: Chun Li, Sidney Wallace, Dong-Fang Yu, David J. Yang
-
Patent number: 7326730Abstract: The present invention provides novel aminoadamantane derivatives, methods of making the derivatives, compositions including the novel aminoadamantane derivatives, and methods for the treatment and prevention of neurological diseases using the derivatives and compositions There are a variety of neurological disorders that can be treated using the present invention, including, for example, the following: neurological disorders arising from trauma, ischemic or hypoxic conditions that can be treated include stroke, hypoglycemia, cerebral ischemia, cardiac arrest, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest and hypoglycemic neuronal damage; neurodegenerative disorders such as epilepsy, Alzheimer's disease, Huntington's disease Parkinsonism, and amyotrophic lateral sclerosis; other diseases or disorders such as convulsion, pain, depression, anxiety, schizophrenia, muscle spasms, migraine headaches, urinary incontinence, nicotine withdrawal, opiate tolerance and withdrawal, emesis, brain edemaType: GrantFiled: November 17, 2005Date of Patent: February 5, 2008Assignee: Adamas Pharmaceuticals, Inc.Inventors: Yuqiang Wang, Wenqing Ye, James W. Larrick, Jonathan S. Stemler, Stuart A. Lipton
-
Patent number: 7141606Abstract: The invention provides a new use of compounds for formula 1 or 1A or a pharmaceutically acceptable salt thereof. The compounds are useful in the treatment of insomnia and related disorders.Type: GrantFiled: May 18, 2001Date of Patent: November 28, 2006Assignee: Warner-Lambert CompanyInventors: Justin Stephen Bryans, Leonard Theodore Meltzer
-
Patent number: 7135496Abstract: Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.Type: GrantFiled: October 28, 2002Date of Patent: November 14, 2006Assignee: PG-TXL Company, L.P.Inventors: Chun Li, Sidney Wallace, Dong-Fang Yu, David Yang
-
Patent number: 7081477Abstract: The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods.Type: GrantFiled: August 12, 2004Date of Patent: July 25, 2006Assignee: The Children's Medical Center CorporationInventors: Robert John D'Amato, Moses Judah Folkman
-
Patent number: 7045524Abstract: Pleuromutilin compounds of the formula: are of use in anti-bacterial therapy.Type: GrantFiled: November 12, 2001Date of Patent: May 16, 2006Assignee: SmithKline Beecham p.l.c.Inventors: David Kenneth Dean, Antoinette Naylor, Andrew Kenneth Takle
-
Patent number: 6982282Abstract: An emulsion of ?-tocopherol, stabilized by biocompatible surfactants, as a vehicle or carrier for therapeutic drugs, which is substantially ethanol free and which can be administered to animals or humans via various routes is disclosed. Also included in the emulsion is PEGylated vitamin E. PEGylated ?-tocopherol includes polyethylene glycol subunits attached by a succinic acid diester at the ring hydroxyl of vitamin E and serves as a primary surfactant, stabilizer and a secondary solvent in emulsions of ?-tocopherol.Type: GrantFiled: May 17, 2002Date of Patent: January 3, 2006Assignee: Sonus Pharmaceuticals, Inc.Inventors: Karel J. Lambert, Panayiotis P. Constantinides, Steven C. Quay
-
Patent number: 6930128Abstract: The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods.Type: GrantFiled: July 10, 2003Date of Patent: August 16, 2005Assignee: The Children's Medical Center CorporationInventors: Robert John D'Amato, Moses Judah Folkman
-
Patent number: 6919376Abstract: Compositions and methods of using an MT103 family member, wherein MT103 is the chemical N,N-dicyclohexyl-(1S)-isoborneol-10-sulfonamide. Uses of the compositions include cancer therapy, antibacterials, antifungals, induction of apoptosis, and hormonal antagonists.Type: GrantFiled: September 20, 2002Date of Patent: July 19, 2005Assignee: Medisyn Technologies, Inc.Inventors: Javier Llompart, Jorge Galvez
-
Patent number: 6906046Abstract: Benzobicyclooctane compounds, their use in inhibiting cellular events involving TNF-? and IL-8, and in the treatment of inflammation events in general; a combinatorial library of diverse bicyclooctanes and process for their synthesis as a library and as individual compounds.Type: GrantFiled: December 11, 2001Date of Patent: June 14, 2005Assignee: Celltech R & D Inc.Inventors: Randy W. Jackson, Ihab Darwish, Ted A. Baughman, J. Jeffry Howbert
-
Patent number: 6884817Abstract: Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.Type: GrantFiled: May 17, 2002Date of Patent: April 26, 2005Assignee: PG-TXL Company, L.P.Inventors: Chun Li, Sidney Wallace, Dong-Fang Yu, David J. Yang
-
Patent number: 6730699Abstract: Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.Type: GrantFiled: November 20, 2002Date of Patent: May 4, 2004Assignee: PG-TXL Company, L.P.Inventors: Chun Li, Sidney Wallace, Dong-Fang Yu, David Yang
-
Patent number: 6727280Abstract: The present invention provides methods for administering a taxane composition for the treatment of cancer. In one aspect, the compositions are not diluted prior to administration. Some embodiments provide methods for administering a taxane as a bolus injection or an intravenous infusion in less than about 30 minutes. In other aspects, the invention provides methods for administering a taxane to provide high concentrations of the taxane in blood or in tumors. Another aspect provides methods for administering a taxane to provide anti-tumor activities against solid tumors. In some embodiments, the methods provide anti-tumor activities against tumors that were resistant to conventional taxane administration methods. In some embodiments, the methods provide anti-tumor activities against colorectal tumors.Type: GrantFiled: July 1, 2002Date of Patent: April 27, 2004Assignee: Sonus Pharmaceuticals, Inc.Inventors: Nagesh Palepu, Dean Kessler, Alexander K. Tustian, Steven C. Quay, Panayiotis P. Constantinides, Karel J. Lambert
-
Patent number: 6620845Abstract: The present invention provides novel aminoadamantane derivatives, methods of making the derivatives, compositions including the novel aminoadamantane derivatives, and methods for the treatment and prevention of neurological diseases using the derivatives and compositions.Type: GrantFiled: July 19, 2002Date of Patent: September 16, 2003Assignee: NeuroMolecular, Inc.Inventors: Yuqiang Wang, Wenqing Ye, James W. Larrick, Jonathan S. Stemler, Stuart A. Lipton
-
Patent number: 6472426Abstract: Polyamines having the formula: wherein R1 and R2 are alkyl, aralkyl or aryl having up to 10 carbon atoms; and a and b may be the same or different and are integers from 1 to 8; or a salt thereof with a pharmaceutically acceptable acid. Anti-neoplastic, anti-diarrheal, anti-peristaltic, gastro-intestinal anti-spasmodic, anti-viral, anti-retroviral, anti-psoriasis and insecticidal compositions comprising biologically effective amounts of the above-described amines and biologically acceptable carriers therefor are also disclosed, as well as methods of treatment, administration or application of biologically effective amounts of the polyamines of the invention. Also disclosed are methods for preparing the polyamines of the invention.Type: GrantFiled: July 18, 2001Date of Patent: October 29, 2002Assignee: University of Florida Research Foundation, Inc.Inventor: Raymond J. Bergeron, Jr.